Gastrointestinal effects such as nausea, early satiety, and changes in bowel habits are common, though typically transient and improved with gradual dose titration [30]
The Phase 3 data coming out of Eli Lilly's TRIUMPH program shows weight loss numbers that make semaglutide and tirzepatide look modest by comparison
US patent US20200005900A1 (2021)
These included: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite These effects were generally dose-dependent, occurring more frequently and with greater severity at higher doses
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
It also stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which promotes tissue growth, supports protein synthesis, and contributes to overall metabolic regulation